Report scope. This 2026 Drug Asset Due Diligence Report evaluates Pelcitoclax as a potential licensing, partnership, acquisition, or option asset. The review separates verified evidence from open diligence questions across clinical development, intellectual property, market positioning, and transaction precedent.
Executive recommendation: CONDITIONAL GO
Pelcitoclax is a Small molecule drug associated with Bcl-2 x Bcl-xl and a global highest development stage of Phase 2. The lead disclosed indication is Non-Small Cell Lung Cancer. The current evidence supports a CONDITIONAL GO posture, subject to confirmation of study-level data, ownership, patent coverage, manufacturing readiness, and regional rights.
Decision memo
- Asset: Pelcitoclax
- Target: Bcl-2 x Bcl-xl
- Lead indication: Non-Small Cell Lung Cancer
- Highest phase: Phase 2
- Matched trials: 12
- Matched result records: 5
- Matched asset deals: 2
Use PatSnap Life Sciences MCP servers to validate the Pelcitoclax diligence evidence.
1. Asset identity and development status
The first diligence task is entity resolution. Teams should reconcile development codes, nonproprietary names, salts, formulations, combinations, sponsors, and predecessor owners before relying on portfolio counts. For Pelcitoclax, the MCP profile identifies Bcl-2 x Bcl-xl as the primary target context and Non-Small Cell Lung Cancer as the lead indication. Global phase labels are useful orientation points, but investment decisions require country- and indication-level status verification.
Confirm the exact molecule, formulation, route, dose, biomarker definition, and current sponsor. Review discontinuations separately from active development so that an historical high phase is not mistaken for a live program.
Use PatSnap Life Sciences MCP servers to validate the Pelcitoclax diligence evidence.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07508982 | Phase 1/2 | Recruiting | Not disclosed | Not disclosed |
| NCT07428486 | Phase 1 | Withdrawn | Not disclosed | Not disclosed |
| ChiCTR2400094086 | Phase 1 | Not yet recruiting | Not disclosed | Not disclosed |
| NCT05691504 | Phase 1 | Active, not recruiting | Not disclosed | Not disclosed |
| NCT05186012 | Phase 1/2 | Unknown status | Not disclosed | Not disclosed |
| NCT04893759 | Phase 1 | Terminated | Not disclosed | Not disclosed |
| NCT04354727 | Phase 1/2 | Withdrawn | Not disclosed | Not disclosed |
| NCT04210037 | Phase 1/2 | Terminated | Not disclosed | Not disclosed |
| NCT04001777 | Phase 1 | Active, not recruiting | Not disclosed | Not disclosed |
| NCT03387332 | Phase 1 | Terminated | Not disclosed | Not disclosed |
| NCT03080311 | Phase 1 | Completed | Not disclosed | Not disclosed |
| ACTRN12616001597482 | Phase 1 | Completed | Not disclosed | Not disclosed |
The clinical program should be audited for randomization, comparator relevance, dose selection, endpoint hierarchy, multiplicity, analysis population, geographic mix, and readout timing. Early-stage programs require attention to pharmacokinetics, pharmacodynamics, adverse events, dose-limiting toxicities, and the rationale for the expansion dose.
Use PatSnap Life Sciences MCP servers to validate the Pelcitoclax diligence evidence.
3. Clinical readouts: what is known
BCL-2/BCL-xL inhibitor pelcitoclax with osimertinib for <i>EGFR</i> -mutated advanced non-small-cell lung cancer: a phase 1b trial
Study: NCT04001777 (Pubmed | J Immunother Cancer). Phase: Phase 1. Enrollment: 64. Published: 2026-07-01.
DLT = One dose-limiting toxicity occurred at pelcitoclax 240 mg | DLT = One dose-limiting toxicity occurred at pelcitoclax 240 mg
Updated study results of pelcitoclax (APG-1252) combined with osimertinib in patients (pts) with EGFR-mutant non-small cell lung cancer (NSCLC)
Study: NCT04001777 (APG1252NC101, ESMO2023). Phase: Phase 1. Enrollment: 64. Published: 2023-10-22.
PR = 47.5 % | PR = 76.9 %
Updated study results of pelcitoclax (APG-1252) in combination with osimertinib in patients (pts) with EGFR-mutant non–small cell lung cancer (NSCLC).
Study: NCT04001777 (ASCO2022). Phase: Phase 1. Enrollment: 20. Published: 2022-06-02.
DoR(9-month) = 71.4 % (95%CI, 25.8 - 92.0)
First-in-human study of pelcitoclax (APG-1252) in combination with paclitaxel in patients (pts) with relapsed/refractory small-cell lung cancer (R/R SCLC).
Study: NCT04210037 (ASCO2022). Phase: Phase 1/2. Enrollment: 28. Published: 2022-06-02.
ORR = 25 %
Abstract 307: Targeting BCL-2 and BCL-xL with a novel dual inhibitor APG-1252 triggers cell death and inhibits tumor growth in small cell lung cancer models
Study: NCT03080311 (AACR2018). Phase: Phase 1. Enrollment: 50. Published: 2018-07-01.
IC50 = sub - µM or nM µM or nM | IC50 = similar in vitro killing ability as APG - 1252 µM or nM
For every reported endpoint, obtain the protocol, statistical analysis plan, patient disposition, baseline characteristics, subgroup definitions, exposure duration, and full safety tables. Conference abstracts and registry summaries can support screening, but they should not replace source data review in a binding transaction.
Use PatSnap Life Sciences MCP servers to validate the Pelcitoclax diligence evidence.
4. Market and competitive position
The commercial case depends on differentiated efficacy, tolerability, convenience, biomarker reach, treatment setting, and access. A target-level market may be attractive while an individual asset remains undifferentiated. Benchmark Pelcitoclax against approved therapies and clinical competitors in Non-Small Cell Lung Cancer, including likely standards of care at the expected launch date.
Build a scenario model around addressable patients, diagnosis and biomarker rates, line of therapy, duration, net price, uptake, displacement, combination costs, and probability-adjusted timelines. Test slower enrollment, delayed readout, narrower labels, safety restrictions, and competitor launches.
Use PatSnap Life Sciences MCP servers to validate the Pelcitoclax diligence evidence.
5. Transaction precedent and economics
| Date | Transaction | Status | Type | Disclosed value |
|---|---|---|---|---|
| 2021-07-19 | Ascentage Pharma and NCI will collaborate in a CRADA for the non-clinical and clinical development of pelcitoclax for solid tumors. | Active | Collaboration | Not disclosed |
| 2016-02-01 | UNITY Biotechnology | Active | Collaboration, License | Not disclosed |
Transaction records should be normalized for territory, asset scope, phase at signing, option mechanics, development obligations, cost sharing, royalties, milestones, and change-of-control terms. Undisclosed economics must not be converted into invented benchmarks.
6. IP and freedom-to-operate screen
Complete a family-level patent review covering composition of matter, sequence or construct claims, polymorph and salt claims, formulation, dosing, combinations, biomarkers, manufacturing, and method of use. Verify priority, ownership, assignments, prosecution status, term adjustments, extensions, oppositions, and regional coverage. Freedom to operate is a separate legal analysis and should include competitor claims and platform dependencies.
The diligence room should reconcile inventorship, employee and contractor assignments, university or platform licenses, sublicensing restrictions, government rights, and obligations triggered by development milestones or commercialization.
Use PatSnap Life Sciences MCP servers to validate the Pelcitoclax diligence evidence.
7. Principal risks and diligence gates
- Identity risk: resolve all aliases, formulations, combinations, and owners.
- Clinical risk: confirm source data, protocol deviations, endpoint definitions, and safety follow-up.
- Regulatory risk: review agency correspondence, meeting minutes, holds, commitments, and indication-specific pathways.
- IP risk: validate enforceable coverage, remaining life, ownership, and freedom to operate.
- CMC risk: assess process control, analytical methods, comparability, scale-up, supply, and cost of goods.
- Commercial risk: pressure-test differentiation, market access, competitive timing, and realistic adoption.
- Transaction risk: map rights, encumbrances, royalties, options, consent requirements, and change-of-control provisions.
8. Final go/no-go memorandum
CONDITIONAL GO
Proceed only through staged diligence. Before exclusivity or a binding offer, require a verified asset identity package, complete clinical data room, regulatory correspondence, patent-family schedule, freedom-to-operate opinion, CMC package, ownership chain, regional rights map, and risk-adjusted valuation. Any material mismatch between public records and source documents should pause the process until reconciled.
Method note: This report uses PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP data retrieved on 2026-10-14. It is a screening and diligence framework, not medical, legal, regulatory, or investment advice.
